Form 4: Kyverna Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
Karen Walker, Chief Technology Officer of Kyverna Therapeutics, exercised stock options on June 6, 2024.
Summary
- On June 6, 2024, Karen Walker, the Chief Technology Officer of Kyverna Therapeutics, exercised stock options to acquire 9,636 shares of common stock at a price of $4.42 per share.
- Following this transaction, Walker directly owns 82,648 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard insider transaction disclosure and doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings in the company's stock.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine exercise of stock options.
Key Dates
| Date | Description |
|---|---|
| September 13, 2022 | 25% of the original number of shares subject to the option vested. |
| 06/06/2024 | Karen Walker exercised stock options. |
| 06/10/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.